Overview

Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
0
Participant gender:
All
Summary
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus bacteremia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Treatments:
Antithrombins
Argatroban
Dabigatran
Enoxaparin
Thrombin
Criteria
Inclusion Criteria:

- Positive blood culture for staphylococcus aureus

- Symptoms or signs of infection

- Indication for thromboprophylaxis

Exclusion Criteria:

- Contraindication for thromboprophylaxis

- Significant active bleeding or risk of excessive bleeding

- Heparin-induced thrombocytopenia

- Severe liver and kidney disease

- Pregnancy and lactation.